|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
ES2139598T3
(es)
|
1990-07-10 |
2000-02-16 |
Medical Res Council |
Procedimientos para la produccion de miembros de parejas de union especifica.
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
JP2938569B2
(ja)
|
1990-08-29 |
1999-08-23 |
ジェンファーム インターナショナル，インコーポレイティド |
異種免疫グロブリンを作る方法及びトランスジェニックマウス
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
|
WO1993011236A1
(en)
|
1991-12-02 |
1993-06-10 |
Medical Research Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
|
JP3507073B2
(ja)
|
1992-03-24 |
2004-03-15 |
ケンブリッジ アンティボディー テクノロジー リミティド |
特異的結合対の成員の製造方法
|
|
SG48760A1
(en)
|
1992-07-24 |
2003-03-18 |
Abgenix Inc |
Generation of xenogenetic antibodies
|
|
CA2161351C
(en)
|
1993-04-26 |
2010-12-21 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
|
FR2707189B1
(fr)
|
1993-07-09 |
1995-10-13 |
Gradient Ass |
Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
|
|
EP0731842A1
(en)
|
1993-12-03 |
1996-09-18 |
Medical Research Council |
Recombinant binding proteins and peptides
|
|
DE69535243T2
(de)
|
1994-07-13 |
2007-05-10 |
Chugai Seiyaku K.K. |
Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
|
|
DE69637481T2
(de)
|
1995-04-27 |
2009-04-09 |
Amgen Fremont Inc. |
Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
JP5291279B2
(ja)
|
2000-09-08 |
2013-09-18 |
ウニヴェルジテート・チューリッヒ |
反復モジュールを含む反復タンパク質の集合体
|
|
WO2002032925A2
(en)
|
2000-10-16 |
2002-04-25 |
Phylos, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
US20030157561A1
(en)
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
|
CA2451493C
(en)
|
2001-06-22 |
2016-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Cell growth inhibitors containing anti-glypican 3 antibody
|
|
WO2003029462A1
(en)
|
2001-09-27 |
2003-04-10 |
Pieris Proteolab Ag |
Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
|
|
JP4448440B2
(ja)
|
2002-04-30 |
2010-04-07 |
株式会社ディナベック研究所 |
プロテアーゼ依存性トロピズムが改変されたベクター
|
|
WO2003104453A1
(ja)
|
2002-06-05 |
2003-12-18 |
中外製薬株式会社 |
抗体作製方法
|
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
WO2004022595A1
(ja)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
MRL/lprマウスを用いた抗体の作製
|
|
WO2005040229A2
(en)
|
2003-10-24 |
2005-05-06 |
Avidia, Inc. |
Ldl receptor class a and egf domain monomers and multimers
|
|
JP2005168328A
(ja)
|
2003-12-08 |
2005-06-30 |
Hokkaido Univ |
シグナル伝達活性を有する細胞質蛋白質の活性制御方法
|
|
SI2383295T1
(sl)
|
2003-12-10 |
2015-07-31 |
E.R. Squibb & Sons, L.L.C. |
Protitelesa IP-10 in njihova uporaba
|
|
DK1735439T3
(da)
|
2004-04-12 |
2012-02-06 |
Catalyst Biosciences Inc |
Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1
|
|
PT1674111E
(pt)
|
2004-07-09 |
2010-12-15 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-glipicano 3
|
|
JP2008523842A
(ja)
|
2004-12-21 |
2008-07-10 |
セントカー・インコーポレーテツド |
抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途
|
|
EP2439273B1
(en)
|
2005-05-09 |
2019-02-27 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
EP1919931A4
(en)
|
2005-08-31 |
2010-01-20 |
Univ California |
CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF
|
|
AU2006321364B2
(en)
|
2005-12-01 |
2011-11-10 |
Domantis Limited |
Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
|
|
CA2629850A1
(en)
|
2005-12-01 |
2007-06-07 |
Domantis Limited |
Competitive domain antibody formats that bind interleukin 1 receptor type 1
|
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
|
|
EP2402437B1
(en)
|
2006-07-05 |
2016-06-01 |
Catalyst Biosciences, Inc. |
Protease screening methods and proteases identified thereby
|
|
CA2659574C
(en)
|
2006-08-02 |
2017-04-25 |
The Uab Research Foundation |
Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
|
|
US8629244B2
(en)
|
2006-08-18 |
2014-01-14 |
Ablynx N.V. |
Interleukin-6 receptor binding polypeptides
|
|
CA2678626A1
(en)
|
2007-02-28 |
2008-09-04 |
Novimmune S.A. |
Anti-ip-10 antibodies and methods of use thereof
|
|
CA2683791A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains & antagonists
|
|
MX2009013816A
(es)
|
2007-06-21 |
2010-02-24 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos.
|
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
|
AU2016213702C1
(en)
|
2007-08-22 |
2018-11-29 |
Cytomx Therapeutics, Inc. |
Activatable binding polypeptides and methods of identification and use thereof
|
|
JP6035009B2
(ja)
|
2007-08-22 |
2016-11-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
KR20130119990A
(ko)
|
2009-04-10 |
2013-11-01 |
아블린쓰 엔.브이. |
Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
|
|
JP2011026294A
(ja)
|
2009-06-26 |
2011-02-10 |
Canon Inc |
化合物
|
|
CA2769619C
(en)
|
2009-08-17 |
2019-04-30 |
Roche Glycart Ag |
Targeted immunoconjugates
|
|
EP2553101A4
(en)
|
2010-04-02 |
2013-09-04 |
Univ Rochester |
PROTEASE-ACTIVATED CYTOKINES
|
|
US9193791B2
(en)
|
2010-08-03 |
2015-11-24 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects
|
|
JP5753903B2
(ja)
|
2010-08-24 |
2015-07-22 |
ロシュ グリクアート アーゲー |
活性化可能な二重特異性抗体
|
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
|
EP2686020B1
(en)
|
2011-03-17 |
2017-02-22 |
The University of Birmingham |
Re-directed immunotherapy
|
|
CN107903325B
(zh)
*
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
US9975962B2
(en)
|
2012-03-30 |
2018-05-22 |
Bayer Healthcare Llc |
Thrombin/plasmin-regulated antibodies that bind TFPI
|
|
SMT201800253T1
(it)
|
2012-04-06 |
2018-07-17 |
Omeros Corp |
Composizioni e metodi per inibire masp-1 e/o masp-3 per il trattamento di emoglobinuria parossistica notturna
|
|
US20150175698A1
(en)
|
2012-05-22 |
2015-06-25 |
Life Technologies As |
Recombinant antibody compositions and methods of use thereof
|
|
BR112014031689A2
(pt)
|
2012-06-22 |
2017-07-25 |
Cytomx Therapeutics Inc |
anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles
|
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
JP6453208B2
(ja)
|
2013-02-15 |
2019-01-16 |
国立大学法人京都工芸繊維大学 |
抗体のリフォールディング方法、リフォールディングされた抗体の製造方法、リフォールディングされた抗体、及びこれらの利用
|
|
US20150087810A1
(en)
|
2013-09-25 |
2015-03-26 |
Cytomx Therapeutics, Inc. |
Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
EP3628328B1
(en)
|
2014-01-31 |
2022-09-14 |
Cytomx Therapeutics Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
WO2015117930A1
(en)
|
2014-02-06 |
2015-08-13 |
F. Hoffmann-La Roche Ag |
Interleukine 10 immunoconjugates
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
GB201413357D0
(en)
|
2014-07-28 |
2014-09-10 |
Philogen Spa |
Antibodies for treatment and diagnosis
|
|
AU2015323313B2
(en)
|
2014-09-25 |
2021-04-01 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
KR20170083095A
(ko)
|
2014-11-11 |
2017-07-17 |
아뮤닉스 오퍼레이팅 인코포레이티드 |
표적화된 xten 접합체 조성물 및 이의 제조 방법
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
JP6826055B2
(ja)
|
2015-03-13 |
2021-02-03 |
サイトメックス セラピューティクス インコーポレイテッド |
抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
|
|
CN107709363A
(zh)
|
2015-05-01 |
2018-02-16 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
JP7028648B2
(ja)
|
2015-05-04 |
2022-03-02 |
サイトメックス セラピューティクス インコーポレイテッド |
抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法
|
|
MY194184A
(en)
|
2015-05-04 |
2022-11-17 |
Cytomx Therapeutics Inc |
Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
|
|
HK1250037A1
(zh)
|
2015-05-04 |
2018-11-23 |
Cytomx Therapeutics Inc. |
抗-itga3抗体、可活化的抗-itga3抗体、及其使用方法
|
|
WO2016182064A1
(ja)
|
2015-05-13 |
2016-11-17 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
WO2017025698A1
(en)
|
2015-08-11 |
2017-02-16 |
Queen Mary University Of London |
Bispecific, cleavable antibodies
|
|
PE20181891A1
(es)
|
2016-03-22 |
2018-12-11 |
Hoffmann La Roche |
Moleculas biespecificas de celulas t activadas por proteasas
|
|
WO2017220989A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
|
MY200695A
(en)
|
2016-11-03 |
2024-01-11 |
Bristol Myers Squibb Co |
Activatable anti-ctla-4 antibodies and uses thereof
|
|
TW202323287A
(zh)
|
2016-11-28 |
2023-06-16 |
日商中外製藥股份有限公司 |
包含抗原結合域與運送部分的多胜肽
|
|
KR20230073346A
(ko)
|
2016-11-28 |
2023-05-25 |
추가이 세이야쿠 가부시키가이샤 |
리간드 결합 활성을 조정 가능한 리간드 결합 분자
|
|
RU2754058C2
(ru)
|
2016-12-13 |
2021-08-26 |
Астеллас Фарма Инк. |
Антитело к cd73 человека
|
|
EP3630817A1
(en)
|
2017-06-02 |
2020-04-08 |
Merck Patent GmbH |
Polypeptides binding adamts5, mmp13 and aggrecan
|
|
EP3630818A1
(en)
|
2017-06-02 |
2020-04-08 |
Ablynx NV |
Aggrecan binding immunoglobulins
|
|
CA3068841A1
(en)
|
2017-07-03 |
2019-01-10 |
Torque Therapeutics, Inc. |
Fusion molecules targeting immune regulatory cells and uses thereof
|
|
US20190038935A1
(en)
|
2017-08-07 |
2019-02-07 |
Timofey Ignatyev |
Exercise game and apparatus employing color-changing base locations
|
|
CN107602706B
(zh)
|
2017-10-16 |
2020-12-04 |
湖北大学 |
一种切割效率增强的hrv 3c蛋白酶底物突变体及其应用
|
|
MX2020005160A
(es)
|
2017-11-28 |
2020-08-20 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a ligando que tiene actividad de union a ligando ajustable.
|
|
WO2019107380A1
(ja)
|
2017-11-28 |
2019-06-06 |
中外製薬株式会社 |
抗原結合ドメインおよび運搬部分を含むポリペプチド
|
|
KR102020131B1
(ko)
|
2017-12-29 |
2019-09-09 |
박성원 |
광경화성 조성물 및 이를 이용하여 제조된 성형품
|
|
EP3762406A2
(en)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Cytokine prodrugs
|
|
SG11202011308VA
(en)
|
2018-05-14 |
2020-12-30 |
Werewolf Therapeutics Inc |
Activatable cytokine polypeptides and methods of use thereof
|
|
JP7460609B2
(ja)
|
2018-05-14 |
2024-04-02 |
ウェアウルフ セラピューティクス， インコーポレイテッド |
活性化可能なインターロイキン－２ポリペプチド及びその使用方法
|
|
WO2019230866A1
(en)
|
2018-05-30 |
2019-12-05 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide comprising il-1r1 binding domain and carrying moiety
|
|
US12077577B2
(en)
|
2018-05-30 |
2024-09-03 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide comprising aggrecan binding domain and carrying moiety
|
|
WO2019230868A1
(ja)
|
2018-05-30 |
2019-12-05 |
中外製薬株式会社 |
単ドメイン抗体含有リガンド結合分子
|
|
WO2020061526A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Conditionally activated target-binding molecules
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
CA3115096A1
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
BR112021023735A2
(pt)
|
2019-06-05 |
2022-01-04 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação de sítio de clivagem de anti-corpo
|
|
WO2020246567A1
(ja)
|
2019-06-05 |
2020-12-10 |
中外製薬株式会社 |
プロテアーゼ基質、及びプロテアーゼ切断配列を含むポリペプチド
|
|
JP7682150B2
(ja)
|
2019-07-25 |
2025-05-23 |
ザ・ユニバーシティ・オブ・シカゴ |
プロテアーゼ活性化治療剤を含む組成物および方法
|
|
CN115943210A
(zh)
|
2020-01-20 |
2023-04-07 |
中外制药株式会社 |
配体结合融合蛋白
|
|
EP4373862A1
(en)
|
2021-07-19 |
2024-05-29 |
Chugai Seiyaku Kabushiki Kaisha |
Protease-mediated target specific cytokine delivery using fusion polypeptide
|